Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTEJV1)

• Drug Name: BAY 60-6583 Drug Info
• Synonyms: BAY-60-6583; BAY60-6583

Indication

Disease Entry	ICD 11	Status	REF
Myocardial ischemia	BA6Z	Preclinical	[1]

• Cross-matching ID:
  PubChem CID: 11717831
  ChEBI ID: CHEBI:131358
  CAS Number: CAS 910487-58-0
  TTD Drug ID: DMTEJV1

Molecule-Related Drug Atlas

Drug(s) Targeting Adenosine A3 receptor (ADORA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IB-MECA	DM9G5XD	Psoriasis vulgaris	EA90	Phase 3	[4]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[5]
NITD609	DMQHBSX	Malaria	1F40-1F45	Phase 2	[6]
CF102	DMP56WJ	Hepatocellular carcinoma	2C12.02	Phase 2	[7]
SCH-442416	DMQ2K1V	N. A.	N. A.	Phase 1	[8]
AST-004	DM5WMG7	Stroke	8B20	Phase 1	[9]
BEMESETRON	DMSPJX9	N. A.	N. A.	Discontinued in Phase 3	[10]
CF602	DM0ULO2	Inflammation	1A00-CA43.1	Preclinical	[7]
CF502	DMQSJ20	Inflammation	1A00-CA43.1	Preclinical	[7]
METHYLTHIOADENOSINE	DMC8J6F	Multiple sclerosis	8A40	Terminated	[11]

Drug(s) Targeting Adenosine A2b receptor (ADORA2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Adenosine	DMM2NSK	Paroxysmal supraventricular tachycardia	BC81.Z	Approved	[12]
Vidarabine	DM0N85H	Hepatosplenic T-cell lymphoma		Approved	[12]
A295	DM55GO2	Aggressive cancer	2A00-2F9Z	IND submitted	[13]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[5]
YT-146	DM3YVKQ	Hypertension	BA00-BA04	Phase 2	[14]
AB928	DMDOXMN	Metastatic colorectal cancer	2B91	Phase 1/2	[15]
KF-17837	DMQ6DLZ	Parkinson disease	8A00.0	Phase 1	[16]
Xanthine	DMFBOQ7	Apnea	MD11.0	Phase 1	[17]
CVT-6883	DMY84TW	Asthma	CA23	Phase 1	[18]
PBF-1129	DMOPGXM	Non-small-cell lung cancer	2C25.Y	Phase 1	[15]

Drug(s) Targeting Adenosine A1 receptor (ADORA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Caffeine	DMKBJWP	Allergic rhinitis	CA08.0	Approved	[19]
Rolofylline	DMSZPR3	Heart failure	BD10-BD13	Phase 3	[20]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[5]
AMP-579	DMJ4GPR	Hyperlipidaemia	5C80	Phase 2	[21]
SELODENOSON	DMQM3IX	Cardiac arrhythmias	BC9Z	Phase 2	[22]
Apaxifylline	DMQMV9F	Cognitive impairment	6D71	Phase 2	[23]
SLV320	DM867BJ	Heart failure	BD10-BD13	Phase 2	[24]
DTI-0009	DMV84OK	Atrial fibrillation	BC81.3	Phase 2	[22]
Capadenoson	DMYWO62	Atrial fibrillation	BC81.3	Phase 2	[25]
BAY 1067197	DM4JGNH	Heart failure	BD10-BD13	Phase 2	[26]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine A1 receptor (ADORA1)	TTK25J1	AA1R_HUMAN	Agonist	[2]
Adenosine A2b receptor (ADORA2B)	TTNE7KG	AA2BR_HUMAN	Agonist	[3]
Adenosine A3 receptor (ADORA3)	TTJFY5U	AA3R_HUMAN	Agonist	[2]

References

• [1] Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
• [2] Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007 Sep;43(3):262-71.
• [3] Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation. 2007 Mar 27;115(12):1581-90.
• [4] A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993 Dec 20;336(1):57-60.
• [5] 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
• [6] Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
• [7] 2011 Pipeline of Can-Fite BioPharm.
• [8] Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5690-4.
• [9] Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke. Stroke. 2022 Jan;53(1):238-248.
• [10] 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
• [11] Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique aden... J Med Chem. 2004 Apr 22;47(9):2243-55.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [13] Clinical pipeline report, company report or official report of Klus Pharma
• [14] Identification of adenosine A2 receptor-cAMP system in human aortic endothelial cells. Biochem Biophys Res Commun. 1994 Mar 15;199(2):905-10.
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. J Med Chem. 1993 Nov 12;36(23):3731-3.
• [17] Role of adenosine in asthma. Drug Dev Res. 1996;39:333-6.
• [18] GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J Pharmacol Exp Ther. 2012 Dec;343(3):587-95.
• [19] Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.
• [20] Association between the PDE4D gene and ischaemic stroke in the Chinese Han population. Clin Sci (Lond). 2009 Aug 17;117(7):265-72.
• [21] Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53.
• [22] Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May;1808(5):1290-308.
• [23] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004779)
• [24] Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart. Clin Sci (Lond). 2009 Jul 16;117(4):157-64.
• [25] A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs. 2008 Dec;17(12):1901-10.
• [26] Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Current Issue vol. 111 no. 12 Celine Valant, 4614-4619.